Pharmaids Pharmaceuticals Limited has announced a key leadership change with the resignation of Dr. Sidde Gowda from his position as Vice President-Operations. The resignation was submitted on December 10, 2025, and takes effect from the close of business hours on the same date.

Resignation Details

The company has filed the mandatory disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure provides comprehensive information about the senior management personnel change.

Reason for Resignation

According to the official disclosure, Dr. Sidde Gowda has tendered his resignation due to personal reasons and pre-occupation with other commitments. In his resignation letter addressed to the Board of Directors, Dr. Gowda confirmed that there are no other material reasons for his resignation beyond the stated personal commitments.

Regulatory Compliance

Pharmaids Pharmaceuticals Limited has ensured full compliance with regulatory requirements by filing the necessary disclosures with BSE Limited. The company's filing includes all details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI Master Circular dated November 11, 2024.

Company Information

Pharmaids Pharmaceuticals Limited operates from its registered office at Unit 201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore 560013. The company secretary and compliance officer, Prasanna Subramanya Bhat, signed the regulatory disclosure documents.

Dr. Gowda expressed his sincere gratitude to the Board of Directors and extended his best wishes for the company's future in his resignation letter. The departure represents a change in the company's senior management structure as it continues its operations in the pharmaceutical sector.

Pharmaids Pharmaceuticals Limited has officially confirmed the appointment of Dr. Yogananda Moolemath as Independent Director effective January 01, 2026, following successful shareholder approval through postal ballot. The company has now filed the requisite regulatory disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Postal Ballot Results Overview

The company successfully concluded its postal ballot process on December 31, 2025, with shareholders approving key board appointments and remuneration proposals through remote e-voting. The postal ballot results were declared on January 02, 2026.

Independent Director Appointment Approved

Dr. Yogananda Moolemath's appointment as Independent Director was approved as a Special Resolution with overwhelming support from shareholders. The appointment follows the Board's earlier decision based on the recommendation of the Nomination and Remuneration Committee.

Director Profile and Qualifications

Dr. Yogananda Moolemath brings extensive expertise to the board as a European Registered Toxicologist (ERT) with a PhD in Toxicology and over 30 years of experience in Drug Discovery & Development, toxicology, regulatory science and research leadership.

Regulatory Compliance and Disclosure

The company has fulfilled all regulatory requirements under SEBI regulations, with Company Secretary Prasanna Subramanya Bhat confirming the appointment through official communication to BSE Limited. The disclosure confirms that Dr. Moolemath is not debarred from holding directorship by any regulatory authority.

Board Restructuring Progress

With Dr. Moolemath's appointment confirmed, the company's board restructuring initiatives continue to strengthen governance. The appointment complements other recent leadership changes, including the designation of Mr. P.N Vijay as Chairman and Dr. S.N Vinaya Babu as Vice Chairman in December 2025.

The successful completion of the postal ballot process and official appointment marks a significant milestone in Pharmaids Pharmaceuticals' governance enhancement, bringing specialized pharmaceutical industry expertise to the board through Dr. Moolemath's extensive background in drug development and regulatory affairs.